{"id":"glulisine-insulin-glargine-insulin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypoglycemia"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"null","effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Glulisine insulin and glargine insulin work by binding to insulin receptors on the surface of cells, triggering a signaling cascade that ultimately leads to the uptake of glucose from the bloodstream into cells. This process helps to lower blood glucose levels and improve glycemic control.","oneSentence":"Glulisine insulin and glargine insulin are long-acting insulin analogs that mimic the action of human insulin, stimulating glucose uptake in cells and lowering blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:08.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes"},{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07070752","phase":"PHASE3","title":"Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2023-04-14","conditions":"Type 1 Diabetes Mellitis","enrollment":224},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT05036876","phase":"NA","title":"Degludec Glargine U300 Hospital Study","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2021-10-10","conditions":"Type 2 Diabetes","enrollment":220},{"nctId":"NCT02871089","phase":"NA","title":"Closed Loop From Onset in Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":96},{"nctId":"NCT02518945","phase":"PHASE3","title":"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2015-08","conditions":"Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT03359837","phase":"PHASE4","title":"Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":384},{"nctId":"NCT03529123","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-06-19","conditions":"Type 2 Diabetes Mellitus","enrollment":247},{"nctId":"NCT03260868","phase":"PHASE4","title":"Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-19","conditions":"Type 1 Diabetes Mellitus","enrollment":15},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT03328845","phase":"PHASE4","title":"Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2017-01-20","conditions":"Type 1 Diabetes Mellitus","enrollment":300},{"nctId":"NCT04157738","phase":"PHASE4","title":"A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-11-27","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":24},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT03013985","phase":"PHASE4","title":"Glargine U300 Hospital Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2017-05-17","conditions":"Type 2 Diabetes","enrollment":247},{"nctId":"NCT02987751","phase":"PHASE4","title":"A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","startDate":"2016-12-29","conditions":"Type2 Diabetes","enrollment":200},{"nctId":"NCT01194245","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 1","enrollment":135},{"nctId":"NCT01855243","phase":"NA","title":"Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM","status":"COMPLETED","sponsor":"Cairo University","startDate":"2010-03","conditions":"Diabetes Mellitus (DM)","enrollment":63},{"nctId":"NCT00979628","phase":"PHASE4","title":"Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Guillermo Umpierrez, MD","startDate":"2010-01","conditions":"Type 2 Diabetes, Hyperglycemia","enrollment":375},{"nctId":"NCT00590044","phase":"PHASE4","title":"Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)","status":"COMPLETED","sponsor":"Emory University","startDate":"2007-12","conditions":"Diabetic Ketoacidosis","enrollment":74},{"nctId":"NCT01792830","phase":"PHASE3","title":"Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-10","conditions":"Poor Glycemic Control","enrollment":175},{"nctId":"NCT01594060","phase":"PHASE4","title":"Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-06","conditions":"Diabetes Mellitus Type 2","enrollment":36},{"nctId":"NCT03051243","phase":"PHASE3","title":"Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2017-10-01","conditions":"DM2","enrollment":60},{"nctId":"NCT03112538","phase":"PHASE4","title":"Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy","status":"UNKNOWN","sponsor":"Clinical Research Centre, Malaysia","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":118},{"nctId":"NCT00911625","phase":"PHASE4","title":"Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency","status":"COMPLETED","sponsor":"Loyola University","startDate":"2009-01-21","conditions":"Type 2 Diabetes, Renal Insufficiency","enrollment":114},{"nctId":"NCT00824668","phase":"PHASE1","title":"Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT01768559","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-01","conditions":"Type 2 Diabetes","enrollment":894},{"nctId":"NCT01234597","phase":"PHASE4","title":"Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-12","conditions":"Diabetes Mellitus, Type 2","enrollment":219},{"nctId":"NCT00115570","phase":"PHASE3","title":"Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-04","conditions":"Diabetes Mellitus, Insulin-Dependent","enrollment":572},{"nctId":"NCT02276196","phase":"PHASE4","title":"Effect of LIXIsenatide on the Renal System","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-09","conditions":"Diabetic Kidney Disease, Diabetic Nephropathy, Diabetes Mellitus","enrollment":40},{"nctId":"NCT00467649","phase":"PHASE4","title":"A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT01131052","phase":"PHASE4","title":"Diabetes in the Elderly: Prospective Study","status":"COMPLETED","sponsor":"Guillermo Umpierrez","startDate":"2011-03","conditions":"Diabetes, Hyperglycemia","enrollment":150},{"nctId":"NCT00927524","phase":"NA","title":"Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2005-04","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT02278913","phase":"PHASE4","title":"Basal Bolus Versus Human Insulin in Hospitalized Patients With Diabetes in Paraguay","status":"COMPLETED","sponsor":"Universidad Nacional de Asunción","startDate":"2009-04","conditions":"Hyperglycemia, Diabetes","enrollment":134},{"nctId":"NCT01194258","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type II","enrollment":132},{"nctId":"NCT00528918","phase":"NA","title":"Comparison of Apidra to Regular Insulin in Hospitalized Patients","status":"COMPLETED","sponsor":"Carl T. Hayden VA Medical Center","startDate":"2007-06","conditions":"Diabetes Mellitus, Type II","enrollment":300},{"nctId":"NCT01087567","phase":"PHASE4","title":"INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"Ohio University","startDate":"2010-07","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT01204593","phase":"PHASE4","title":"baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-11","conditions":"Diabetes Mellitus, Type 1","enrollment":206},{"nctId":"NCT00596687","phase":"PHASE4","title":"Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2007-12","conditions":"Type 2 Diabetes, Inpatient Hyperglycemia","enrollment":234},{"nctId":"NCT00394407","phase":"PHASE4","title":"Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-09","conditions":"Diabetes, Hyperglycemia","enrollment":130},{"nctId":"NCT01122979","phase":"PHASE4","title":"Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-07","conditions":"Diabetes Mellitus, Type 2","enrollment":72},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT00474838","phase":"PHASE4","title":"Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2007-04","conditions":"Type 2 Diabetes Mellitus, Pancreatic Beta Cell Function, Glucotoxicity","enrollment":112},{"nctId":"NCT00943709","phase":"PHASE3","title":"Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia","status":"WITHDRAWN","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2009-05","conditions":"Hyperglycemia, Leukemia","enrollment":""},{"nctId":"NCT01212913","phase":"PHASE4","title":"Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 2","enrollment":161},{"nctId":"NCT01079364","phase":"PHASE4","title":"Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-01","conditions":"Diabetes Mellitus, Type 2","enrollment":52},{"nctId":"NCT01121835","phase":"PHASE4","title":"Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":934},{"nctId":"NCT00965549","phase":"PHASE4","title":"Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":463},{"nctId":"NCT01202474","phase":"PHASE4","title":"Apidra Children & Adolescents Study","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-05","conditions":"Diabetes Mellitus, Type 1","enrollment":100},{"nctId":"NCT01203111","phase":"PHASE4","title":"Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":207},{"nctId":"NCT00964574","phase":"PHASE4","title":"Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 1","enrollment":68},{"nctId":"NCT00925977","phase":"NA","title":"Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents","status":"TERMINATED","sponsor":"Rabin Medical Center","startDate":"2009-07","conditions":"Diabetes Type 1","enrollment":44},{"nctId":"NCT01081938","phase":"PHASE4","title":"Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT01013571","phase":"PHASE4","title":"Self Titration With Apidra to Reach Target Study (START)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 2","enrollment":493},{"nctId":"NCT01417897","phase":"PHASE4","title":"Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study","status":"UNKNOWN","sponsor":"ikfe-CRO GmbH","startDate":"2011-09","conditions":"Type 2 Diabetes Mellitus","enrollment":12},{"nctId":"NCT01500850","phase":"PHASE4","title":"Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use","status":"UNKNOWN","sponsor":"ikfe-CRO GmbH","startDate":"2011-10","conditions":"Insulin-requiring Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT00360698","phase":"PHASE4","title":"Insulin Glulisine in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-07","conditions":"Diabetes Mellitus, Type 2","enrollment":106},{"nctId":"NCT00384085","phase":"PHASE4","title":"Insulin Glargine \"All to Target\" Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-05","conditions":"Diabetes Mellitus, Type 2","enrollment":588},{"nctId":"NCT00670228","phase":"PHASE3","title":"Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction","status":"TERMINATED","sponsor":"Sanofi","startDate":"2008-04","conditions":"AMI","enrollment":34},{"nctId":"NCT00283049","phase":"PHASE4","title":"Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control","status":"TERMINATED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Diabetes Mellitus, Type 2","enrollment":390},{"nctId":"NCT00135083","phase":"PHASE3","title":"Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Diabetes Mellitus, Type 2","enrollment":347},{"nctId":"NCT00135096","phase":"PHASE3","title":"Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Diabetes Mellitus, Type 2","enrollment":345},{"nctId":"NCT00135057","phase":"PHASE3","title":"Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-04","conditions":"Diabetes Mellitus, Type 2","enrollment":281},{"nctId":"NCT01192711","phase":"PHASE3","title":"Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice","status":"UNKNOWN","sponsor":"Consorzio Mario Negri Sud","startDate":"2009-05","conditions":"Type 1 Diabetes","enrollment":130},{"nctId":"NCT00640991","phase":"PHASE3","title":"REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2008-04","conditions":"Hyperglycemia, Cardiovascular Diseases, Myocardial Infarction","enrollment":500},{"nctId":"NCT01143948","phase":"PHASE4","title":"Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2011-01","conditions":"Type 2 Diabetes, Liver Cirrhosis","enrollment":45},{"nctId":"NCT00272064","phase":"PHASE3","title":"ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-10","conditions":"Diabetes Mellitus, Type 2","enrollment":352},{"nctId":"NCT00271284","phase":"PHASE3","title":"Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-10","conditions":"Diabetes Mellitus, Type 1","enrollment":88},{"nctId":"NCT00272012","phase":"PHASE3","title":"OPAL - Insulin Glulisine, Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Diabetes Mellitus Type 2","enrollment":396},{"nctId":"NCT00545337","phase":"PHASE3","title":"Glulisine + Lantus in Type I Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-09","conditions":"Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT00539448","phase":"PHASE4","title":"Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-04","conditions":"Diabetes Mellitus, Type 1","enrollment":98},{"nctId":"NCT00397553","phase":"PHASE3","title":"Insulin Glulisine, Diabetes Mellitus Type 1","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-01","conditions":"Diabetes Mellitus, Type 1","enrollment":104},{"nctId":"NCT00174642","phase":"PHASE3","title":"Opposing Step-by-step Insulin Reinforcement to Intensified Strategy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-12","conditions":"Diabetes Mellitus, Type 2","enrollment":811},{"nctId":"NCT00467376","phase":"PHASE3","title":"Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-01","conditions":"Diabetes Mellitus","enrollment":485},{"nctId":"NCT00174668","phase":"PHASE3","title":"Insulin Glulisine in Diabetes Mellitus, Type 2","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 2","enrollment":311},{"nctId":"NCT00546702","phase":"PHASE3","title":"Glulisine + Lantus in Type I Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-09","conditions":"Diabetes Mellitus, Type 1","enrollment":142},{"nctId":"NCT00135941","phase":"PHASE3","title":"Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-08","conditions":"Diabetes Mellitus","enrollment":582}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Apidra, Lantus"],"phase":"phase_3","status":"active","brandName":"glulisine insulin, glargine insulin","genericName":"glulisine insulin, glargine insulin","companyName":"Population Health Research Institute","companyId":"population-health-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glulisine insulin and glargine insulin are long-acting insulin analogs that mimic the action of human insulin, stimulating glucose uptake in cells and lowering blood glucose levels. Used for Type 1 diabetes, Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}